Du är här

2016-05-12

AstraZeneca: AstraZeneca to highlight the breadth of its respiratory medicines at American Thoracic Society 2016 International Conference

New data reflect advancements across novel inhaled therapies,
respiratory biologics and research into underlying disease pathways

AstraZeneca will demonstrate the breadth and depth of its
industry-leading respiratory disease medicines with more than 60
abstracts and scientific presentations at the American Thoracic
Society (ATS) 2016 International Conference in San Francisco,
California, 13-18 May 2016.

Data support AstraZeneca's novel inhaled combinations, respiratory
biologics and innovative science, which targets new pathways in
asthma and chronic obstructive pulmonary disease (COPD). Highlights
include:

· 14 abstracts focused on unmet need in COPD as well as Bevespi
Aerosphere (glycopyrrolate/formoterol fumarate), recently approved by
the US FDA,
(https://www.astrazeneca.com/media-centre/press-releases/2016/bevespi-aer...)
a novel fixed-dose dual bronchodilator pMDI utilising the latest
co-suspension technology for the treatment of COPD, including 24-hour
lung function data compared to tiotropium bromide inhalation spray
and placebo.

· Biomarker data on benralizumab, an anti-eosinophil monoclonal
antibody currently in Phase III trials in both severe asthma and
COPD. The data evaluate the potential for high baseline blood
eosinophils as well as baseline serum biomarkers of the IL-13 pathway
to predict treatment response. These data may be of value for both
benralizumab and tralokinumab (IL-13 monoclonal antibody).

· Data highlighting breakthrough science aimed at addressing and
potentially modifying the underlying causes of respiratory diseases,
with a research focus on four key biological pathways: eosinophilic
disease, Th2-driven disease, epithelial-driven pathobiology and
autoimmunity.

In addition, data will be presented evaluating the effects on lung
function and airway inflammation of Daxas (roflumilast), the oral
PDE4 inhibitor, initiated in addition to standard therapy with
corticosteroids and antibiotics at the onset of an acute exacerbation
of COPD.

Tom Keith-Roach, Vice President, Global Product Strategy for
Respiratory, Inflammation and Autoimmunity, said: "Respiratory is one
of AstraZeneca's main therapy areas and it's exciting that the data
being shared at ATS demonstrate how rapidly our pipeline and
portfolio are developing. We believe Bevespi Aerosphere and
investigational medicines such as benralizumab can make a real
difference in the lives of patients living with respiratory
conditions worldwide."

AstraZeneca key presentations at ATS 2016:

Lead author Abstract title Presentation details

COPD, Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) and
PT010 (budesonide/glycopyrrolate/formoterol)

Ding B A cross OralTuesday, 17 May, 3:00 PMAbstract #A6156
-sectional
assessment of
the burden of
chronic
obstructive
pulmonary
disease (COPD)
symptoms in the
United States
and Europe
using the
National Health
and Wellness
Survey
PINNACLE-1 & Pooled analyses Wednesday, 18 May, 9:00 AM Abstract #A6782
PINNACLE from PINNACLE-1
-2Martinez F and -2; the
novel LAMA/LABA
co-suspension
technology
glycopyrrolate/f
ormoterol fixed
-dose
combination
delivered by
MDI shows
significant
improvement
versus
monocomponents
in patients
with COPD
PINNACLE Safety and Wednesday, 18 May, 9:00 AMAbstract #A6791
-3Hanania N efficacy of a
novel LAMA/LABA
co-suspension
technology
glycopyrrolate/f
ormoterol fixed
-dose
combination
delivered by
MDI: Results of
a one-year
extension study
in patients
with COPD
(PINNACLE-3)
Arora S 24-hour lung Wednesday, 18 May, 9:00 AMAbstract #A6823
function
profile of
novel co
-suspension
glycopyrrolate/f
ormoterol
metered dose
inhaler versus
placebo and
Spiriva®
Respimat®, in
patients with
moderate-to
-very-severe
chronic
obstructive
pulmonary
disease
Arora S 24-hour lung Wednesday, 18 May, 9:00 AMAbstract #A6792
function
following the
novel LAMA/LABA
co-suspension
technology of
glycopyrrolate/f
ormoterol fixed
-dose
combination
MDI, in
patients with
moderate-to
-very-severe
COPD
Martinez F The novel Wednesday, 18 May, 9:00 AMAbstract #A6784
LAMA/LABA co
-suspension
technology of
glycopyrrolate/f
ormoterolfixed
-dose
combination MDI
significantly
improves health
status in
symptomatic
patients with
COPD
Mack P Drug delivery Tuesday, 17 May, 9:00 AMAbstract #A5839
from a novel
LAMA/LABAco
-suspension
technology of
glycopyrrolate/f
ormoterol fixed
-dose
combination
MDI: Evidence
of consistency,
robustness and
patient-use
reliability
Orevillo C Pharmacokinetic Wednesday, 18 May, 9:00 AMAbstract #6827
and safety
profile of a
novel co
-suspension
technology
fixed-dose
combination of
budesonide/glyco
pyrrolate/formot
erol delivered
by metered dose
inhaler (PT010)
in healthy
adult subjects

SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation
Aerosol

Inoue Proportion and Late-Breaker Poster DiscussionTuesday,
H characteristics 17 May, 2:15 PM-4:15 PMAbstract #A7889
of asthma-
chronic
obstructive
pulmonary
disease (COPD)
overlap
syndrome among
COPD patients
in Japan

Respiratory Biologics

Newbold High blood eosinophil Monday, 16 May, 2:15 PMAbstract #A4351
P concentrations and serum
biomarkers of low IL-13
pathway activation at
baseline predict exacerbation
rate reduction by
benralizumab for patients
with moderate to severe
asthma
Ranade Dipeptidyl peptidase 4 (DPP4) Monday, 16 May, 2:15 PMAbstract #A4332
K is a novel predictive
biomarker for the
investigational anti-IL13
targeted therapy tralokinumab

Eklira (aclidinium)

Beier J Improvement in lung Wednesday, 18 May 9:00 AMAbstract #6817
function and symptom
control with aclidinium
bromide versus tiotropium
and placebo in symptomatic
patients with COPD: post
-hoc analysis of a Phase
IIIb study
Magnussen The effect of aclidinium Wednesday, 18 May 9:00 AMAbstract #6820
H bromide 400 µg on lung
function, sleep quality
and physical activity in
patients with chronic
obstructive pulmonary
disease: Results of a
Phase IV pilot study

Duaklir (aclidinium/formoterol)

Miravitilles Efficacy of Wednesday, 18 May 9:00 AMAbstract #6773
M aclidinium/formoterol
on bronchodilation and
symptoms in
symptomatic and
asymptomatic patients
with COPD: pooled
analysis of two Phase
III studies
Singh D Reduction in Wednesday, 18 May 9:00 AMAbstract #A6771
clinically important
deterioration in
chronic obstructive
pulmonary disease in
patients treated with
aclidinium/formoterol
combination

Daliresp/Daxas (roflumilast)

TREATMackay Roflumilast initiated at Tuesday, 17 May 9:00 AMAbstract #A5180
AJ onset of acute
exacerbation of COPD
enhances lung function
recovery: results from
the randomised, double
-blind, placebo
-controlled, parallel
-group trial, Treatment
with Roflumilast at
ExAcerbaTion (TREAT)
TREATMackay Reduction of airway Tuesday, 17 May 9:00 AMAbstract #A5181
AJ inflammation with
roflumilast initiated at
onset of acute
exacerbation of COPD:
results from the
randomised, double-blind,
placebo-controlled,
parallel-group trial,
Treatment with
Roflumilast at
ExAcerbaTion (TREAT)

Emerging and Disease Modification Science

Mardh CK A novel inhaled non Sunday, 15 May, 9:00 AMAbstract #A1329
-steroidal modulator of
inflammation for the
control of asthma; AZD7594
Jackson S Safety and tolerability of Sunday, 15 May, 9:00 AMAbstract #A1326
AZD1419, an inhaled
oligonucleotide-based toll
-like receptor 9 agonist in
healthy volunteers: a
potential new therapy for
asthma
Goransson SIK inhibition: A novel Tuesday, 17 May, 9:00 AMAbstract #5837
M opportun...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.